Freitag, 19. Dezember 2014

Nachtrag - Novartis beendet Kooperation mit Vernalis...

Da das Biotechunternehmen Vernalis an dieser Stelle bereits vor 2 Jahren vorgestellt wurde anbei folgender Nachtrag zu einer heute veröffentlichten Mitteilung des Unternehmens und zwischenzeitlich immer wieder besprochen. Nun kommt heute folgende Nachricht heraus - 

Zitat:

Vernalis plc: Update on AUY922 Development Programme

Published: Dec 19, 2014 2:00 a.m. ET

WINNERSH, UNITED KINGDOM, Dec 19, 2014 (Marketwired via COMTEX) -- Vernalis plc (VER)


Update on AUY922 development programme 


Vernalis plc today announces that Novartis has informed Vernalis that it is has ceased all development work on AUY922, the novel intravenous Hsp90 inhibitor and rights from the programme will now revert to Vernalis. This programme was out-licensed to Novartis in 2004 and since then Vernalis has made no further investment. Novartis has been investigating AUY922 for the treatment of a range of solid cancer tumours. 


The process to hand back programme data will take place in early 2015. When completed, Vernalis will review the data and decide on next steps and how best to take the programme forward. 


Ian Garland, CEO of Vernalis commented, "This is disappointing news, but illustrates the risks involved in new chemical entity drug development and supports our strategic shift to lower risk later stage programmes. This programme had potential to add future value, if it had successfully progressed through development but was not a driver of near term value for Vernalis". 


Notes to Editors 


About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com

Vernalis Forward-Looking Statement"

Kommentar: 

Ein Rückschlag für das Unternehmen - es bleibt abzuwarten, ob das ganze noch eine Zukunft hat. Das Medikament kann eigenen Recherchen zufolge schwere Nebenwirkungen im Bereich der Augen verursachen. Daher dürfte Novartis wahrscheinlich die Studien abgebrochen haben. Ein Einstieg drängt sich angesichts dieses Newsflow nicht auf.

Lesen Sie dazu auch folgenden Beitrag:

Keine Kommentare:

Kommentar veröffentlichen